Skip to search formSkip to main contentSkip to account menu

(124)I-cMAb U36

Known as: 124I-cMAb U36 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Antibody based positron emission tomography (immuno-PET) imaging is of increasing importance to visualize and characterize tumor… 
Highly Cited
2009
Highly Cited
2009
Immuno-PET is an appealing concept in the detection of tumors and planning of antibody-based therapy. For this purpose, the long… 
2008
2008
In patients with head and neck squamous cell carcinoma (HNSCC) radioimmunodiagnosis could offer a more specific and sensitive… 
2006
2006
PurposeWe tested the suitability of the chimeric monoclonal anti-human CD44 splice version 6 antibody (cMAb U36) for targeting… 
2005
2005
PurposeThe purpose of this study was to analyse the properties of the astatinated chimeric MAb (cMAb) U36 as a conjugate to… 
Highly Cited
2004
Highly Cited
2004
PurposeMonoclonal antibodies (MAbs) labelled with 124I are an attractive option for quantitative imaging with positron emission… 
2003
2003
We have evaluated the applicability of the [(4-isothiocyanatobenzylammonio)undecahydro-closo-dodecaborate (1-)] (DABI) linker… 
2002
2002
PURPOSE In an earlier Phase I radioimmunotherapy (RIT) study with rhenium-186-labeled chimeric monoclonal antibody (cMAb) U36 in… 
Highly Cited
2000
Highly Cited
2000
UNLABELLED A phase I therapy study was conducted to determine the safety, maximum tolerated dose (MTD), pharmacokinetics… 
Highly Cited
2000
Highly Cited
2000
Coupling of photosensitizers to tumor‐selective monoclonal antibodies ( MAbs ) is an attractive option for improving the…